Stephen W Fesik

List of Publications by Year
in descending order

67	14,705	87888 38	106344 65
papers	citations	h-index	g-index

69	69	69	17896
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681.	27.8	3,157
2	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. Cancer Research, 2008, 68, 3421-3428.	0.9	1,666
3	Drugging the undruggable RAS: Mission Possible?. Nature Reviews Drug Discovery, 2014, 13, 828-851.	46.4	1,484
4	Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis. Science, 1997, 275, 983-986.	12.6	1,394
5	Twenty years on: the impact of fragments on drug discovery. Nature Reviews Drug Discovery, 2016, 15, 605-619.	46.4	711
6	Structural biology of the Bcl-2 family of proteins. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 83-94.	4.1	602
7	Druggability Indices for Protein Targets Derived from NMR-Based Screening Data. Journal of Medicinal Chemistry, 2005, 48, 2518-2525.	6.4	497
8	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
9	Discovery of Small Molecules that Bind to Kâ€Ras and Inhibit Sosâ€Mediated Activation. Angewandte Chemie - International Edition, 2012, 51, 6140-6143.	13.8	419
10	Privileged Molecules for Protein Binding Identified from NMR-Based Screening. Journal of Medicinal Chemistry, 2000, 43, 3443-3447.	6.4	360
11	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737. Cancer Research, 2007, 67, 1176-1183.	0.9	283
12	Drugging an undruggable pocket on KRAS. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15823-15829.	7.1	280
13	A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery, 2018, 8, 1566-1581.	9.4	250
14	Discovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2013, 56, 15-30.	6.4	248
15	Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. Molecular Cell, 2015, 58, 440-452.	9.7	224
16	NMR-Based Screening of Proteins Containing13C-Labeled Methyl Groups. Journal of the American Chemical Society, 2000, 122, 7898-7904.	13.7	207
17	DRUG DESIGN: Discovering High-Affinity Ligands for Proteins. Science, 1997, 278, 497-499.	12.6	201
18	Fragment-based drug discovery using NMR spectroscopy. Journal of Biomolecular NMR, 2013, 56, 65-75.	2.8	179

#	Article	IF	Citations
19	Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3401-3406.	7.1	165
20	Small molecule Mcl-1 inhibitors for the treatment of cancer. , 2015, 145, 76-84.		145
21	Discovery and Structureâ˜Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo. Journal of Medicinal Chemistry, 2006, 49, 1165-1181.	6.4	126
22	Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. Journal of Medicinal Chemistry, 2016, 59, 2054-2066.	6.4	114
23	Discovery of Tricyclic Indoles That Potently Inhibit Mcl-1 Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2015, 58, 3794-3805.	6.4	84
24	Design of Adenosine Kinase Inhibitors from the NMR-Based Screening of Fragments. Journal of Medicinal Chemistry, 2000, 43, 4781-4786.	6.4	81
25	Fragment-Based Screening of the Bromodomain of ATAD2. Journal of Medicinal Chemistry, 2014, 57, 9687-9692.	6.4	75
26	Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity. Cell Reports, 2019, 26, 2916-2928.e13.	6.4	70
27	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25260-25268.	7.1	69
28	Three-dimensional structures of proteins involved in programmed cell death. Journal of Molecular Biology, 1997, 274, 291-302.	4.2	63
29	Discovery of a Potent Inhibitor of Replication Protein A Proteinâ€“Protein Interactions Using a Fragment-Linking Approach. Journal of Medicinal Chemistry, 2013, 56, 9242-9250.	6.4	59
30	Discovery of Potent 2-Aryl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2018, 61, 5623-5642.	6.4	54
31	Discovery of a Potent Stapled Helix Peptide That Binds to the 70N Domain of Replication Protein A. Journal of Medicinal Chemistry, 2014, 57, 2455-2461.	6.4	49
32	Discovery and biological characterization of potent myeloid cell leukemiaâ€1 inhibitors. FEBS Letters, 2017, 591, 240-251.	2.8	49
33	High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Analytical Biochemistry, 2018, 548, 44-52.	2.4	48
34	Fragment-based screening of programmed death ligand 1 (PD-L1). Bioorganic and Medicinal Chemistry Letters, 2019, 29, 786-790.	2.2	48
35	Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design. Journal of Medicinal Chemistry, 2018, 61, 2410-2421.	6.4	47
36	Discovery of WD Repeat-Containing Protein 5 (WDR5)â€“MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. Journal of Medicinal Chemistry, 2020, 63, 4315-4333.	6.4	47

#	Article	IF	Citations
37	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Journal of Medicinal Chemistry, 2019, 62, 3971-3988.	6.4	44
38	Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS. Journal of Medicinal Chemistry, 2018, 61, 8875-8894.	6.4	41
39	Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5â€"MYC Proteinâ€"Protein Interaction. Journal of Medicinal Chemistry, 2019, 62, 11232-11259.	6.4	40
40	WDR5 is a conserved regulator of protein synthesis gene expression. Nucleic Acids Research, 2020, 48, 2924-2941.	14.5	40
41	A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Analytical Biochemistry, 2012, 421, 742-749.	2.4	39
42	Small Moleculeâ€"Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1. Molecular Cancer Therapeutics, 2018, 17, 1051-1060.	4.1	34
43	Discovery of Aminopiperidine Indoles That Activate the Guanine Nucleotide Exchange Factor SOS1 and Modulate RAS Signaling. Journal of Medicinal Chemistry, 2018, 61, 6002-6017.	6.4	33
44	Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Journal of Medicinal Chemistry, 2020, 63, 656-675.	6.4	33
45	A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. Journal of Biomolecular NMR, 2014, 60, 11-14.	2.8	32
46	Impact of WIN site inhibitor on the WDR5 interactome. Cell Reports, 2021, 34, 108636.	6.4	29
47	Discovery of Proteinâ€"Protein Interaction Inhibitors of Replication Protein A. ACS Medicinal Chemistry Letters, 2013, 4, 601-605.	2.8	27
48	Targeting WDR5: A WINning Anti-Cancer Strategy?. Epigenetics Insights, 2019, 12, 251686571986528.	2.0	25
49	Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS. ACS Medicinal Chemistry Letters, 2018, 9, 941-946.	2.8	24
50	Targeting MYC through WDR5. Molecular and Cellular Oncology, 2020, 7, 1709388.	0.7	24
51	Discovery of Sulfonamide-Derived Agonists of SOS1-Mediated Nucleotide Exchange on RAS Using Fragment-Based Methods. Journal of Medicinal Chemistry, 2020, 63, 8325-8337.	6.4	20
52	Surface Reengineering of RPA70N Enables Cocrystallization with an Inhibitor of the Replication Protein A Interaction Motif of ATR Interacting Protein. Biochemistry, 2013, 52, 6515-6524.	2.5	19
53	Diphenylpyrazoles as Replication Protein A Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 140-145.	2.8	18
54	Structural Elucidation of Peptide Binding to KLHL-12, a Substrate Specific Adapter Protein in a Cul3-Ring E3 Ligase Complex. Biochemistry, 2020, 59, 964-969.	2.5	17

#	Article	IF	Citations
55	Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Bioorganic and Medicinal Chemistry, 2017, 25, 3087-3092.	3.0	16
56	Small Molecule SOS1 Agonists Modulate MAPK and PI3K Signaling via Independent Cellular Responses. ACS Chemical Biology, 2019, 14, 325-331.	3.4	15
57	Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization. Journal of Medicinal Chemistry, 2022, 65, 6287-6312.	6.4	15
58	Identification and Optimization of Anthranilic Acid Based Inhibitors of Replication Proteinâ€…A. ChemMedChem, 2016, 11, 893-899.	3.2	13
59	Reply to Tran et al.: Dimeric KRAS proteinâ€“protein interaction stabilizers. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3365-3367.	7.1	13
60	Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). Journal of Medicinal Chemistry, 2021, 64, 14757-14772.	6.4	13
61	WIN site inhibition disrupts a subset of WDR5 function. Scientific Reports, 2022, 12, 1848.	3.3	10
62	Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells. NAR Cancer, 2022, 4, zcac007.	3.1	8
63	Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors. Biochemistry, 2018, 57, 4952-4958.	2.5	6
64	Recent advancements in the discovery of proteinâ€“protein interaction inhibitors of replication protein A. MedChemComm, 2017, 8, 259-267.	3.4	5
65	BAX-BAK heterodimer as a pharmacodynamic biomarker of on-target drug action of Mcl-1 inhibitors to evaluate in-vivo effectiveness.. Journal of Clinical Oncology, 2018, 36, 2582-2582.	1.6	1
66	Abstract IA13: Discovery of K-Ras inhibitors for the treatment of cancer. , 2014, , .		0
67	Abstract IA17: Discovery of K-Ras inhibitors for the treatment of cancer. , 2014, , .		0